BELGRADE, SERBIA, May 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK)http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant new advances recently announced regarding the drug Ribavirin; one of the drugs with which they are currently conducting research.
On Wednesday, May 13, 2009, Health and Medicine Magazine reported that:
A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universite de Montreal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.
Interested readers can view a CTV news report on the story at http://watch.ctv.ca/news/top-picks/old-drug-new-use/#clip173867 .
The story is of interest as Slavica BioChem is currently conducting research into the use of Ribavirin for use in the treatment of diseases of the Central Nervous system such as Multiple Sclerosis (MS). Studies conducted involved using a combination of ribavirin and tiazofurin and have shown promising results in test animals to date.
One of the benefits of working with established drugs such as ribavirin, which has been in use approximately twenty years, is that the significant experience and history of the drug make it easier to obtain approval for use in new applications, such as the research that has been conducted by Slavica BioChem.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc. 's control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Note this CTV web link is an unauthorized link, provided for the convenience of the reader.
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved